Objectives The detection of myositis autoantibodies (MA) in patients with interstitial lung
disease (ILD) has major implications for diagnosis and management, especially amyopathic …

The aim of this review is to examine and evaluate published literature associated with
idiopathic inflammatory myopathies (IIM) and interstitial lung disease (ILD) based on …

Interstitial lung disease (ILD) frequently complicates the inflammatory myopathies and at
times is the most prominent clinical feature. Over the years, there has been a growing …

Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung
disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody …

Purpose of the review Idiopathic inflammatory myopathies (IIMs) are a group of rare,
heterogeneous connective tissue diseases marked by skeletal muscle inflammation. The …

We read with interest the recent article from Fidler et al.[1] published online in LUNG (March
2019) and the previous article from De Sadeleer et al.[2](March 2018) examining the role of …

Purpose International guidelines recommend screening for connective tissue disease (CTD)
with autoantibodies when evaluating patients with idiopathic interstitial lung disease (ILD) …

Background Acute onset of interstitial lung disease (ILD) has been described in patients with
idiopathic inflammatory myositis (IIM), but controlled studies about this issue are sparse. The …

Objectives The impact of autoantibody profiles on the prognosis for idiopathic inflammatory
myositis–associated interstitial lung disease (IIM-ILD) and myositis spectrum ILD with …

The presence of interstitial lung disease (ILD) is a common and fearsome feature of
idiopathic inflammatory myopathies (IIM). Such patients show radiological pattern of non …